Patent · US Active

Compounds that inhibit MPS1 kinase

US10479788B2 · kind B2 · utility

3Cited by
9References
19Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 8, 2018
Grant dateNov 19, 2019
Priority date
Expiry dateJan 8, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D519/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.